Lourdes Toral‐Barza
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Synthesis and biological activity, Neuroscience and Neuropharmacology Research, Bioactive Compounds and Antitumor Agents, Biochemical and Molecular Research
Most-Cited Works
- → mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.(2001)418 cited
- → Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin(2009)326 cited
- → Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy(2015)221 cited
- → Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2(2010)208 cited
- → Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells(2010)183 cited
- → Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity(2019)169 cited
- → A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis(2008)120 cited
- → ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines(2009)98 cited
- → Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors(2009)97 cited
- → Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy(2008)92 cited